{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:06:34Z","timestamp":1793743594262,"version":"4.6.1"},"reference-count":56,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T00:00:00Z","timestamp":1710979200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"\u201cGINOP-2.3.2-15-2016-00048\u2014STAY ALIVE\u201d","award":["EFOP 3.6.2-16-2017-00006\u2014LIVE LONGER"],"award-info":[{"award-number":["EFOP 3.6.2-16-2017-00006\u2014LIVE LONGER"]}]},{"name":"Human Resources Development Operational Programme","award":["EFOP 3.6.2-16-2017-00006\u2014LIVE LONGER"],"award-info":[{"award-number":["EFOP 3.6.2-16-2017-00006\u2014LIVE LONGER"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Women are typically diagnosed with estrogen receptor-positive breast cancer around the postmenopausal period when declining estrogen levels initiate changes in lipid profiles. Aromatase inhibitors (AI) are used to prevent the progression of cancer; however, a further reduction in estrogen levels may have detrimental effects on lipid levels, which was our working hypothesis. Methods: Our meta-analysis was conducted on the lipid profiles of postmenopausal breast cancer patients at baseline and at different treatment time points. Results: We identified 15 studies, including 1708 patients. Studies using anastrozole (ANA), exemestane (EXE), letrozole (LET), and tamoxifen (TMX) were involved. Subgroup analyses revealed that 3- and 12-month administrations of LET and EXE lead to negative changes in lipid profiles that tend to alter the lipid profile undesirably, unlike ANA and TMX. Conclusions: Our results suggest that, despite statistically significant results, EXE and LET may not be sufficient to cause severe dyslipidemia in patients without cardiovascular comorbidities according to the AHA\/ACC Guideline on the Management of Blood Cholesterol. However, the results may raise the question of monitoring the effects of AIs in patients, especially those with pre-existing cardiovascular risk factors such as dyslipidemia.<\/jats:p>","DOI":"10.3390\/jcm13061818","type":"journal-article","created":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T09:13:08Z","timestamp":1711012388000},"page":"1818","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Aromatase Inhibitors and Plasma Lipid Changes in Postmenopausal Women with Breast Cancer: A Systematic Review and Meta-Analysis"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9955-9901","authenticated-orcid":false,"given":"B\u00e1lint","family":"B\u00e9rczi","sequence":"first","affiliation":[{"name":"Department of Public Health Medicine, Medical School, University of P\u00e9cs, Szigeti \u00fat 12, 7624 P\u00e9cs, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5349-6527","authenticated-orcid":false,"given":"Nelli","family":"Farkas","sequence":"additional","affiliation":[{"name":"Institute for Translational Medicine, Medical School, University of P\u00e9cs, Szigeti \u00fat 12, 7624 P\u00e9cs, Hungary"},{"name":"Institute of Bioanalysis, Medical School, University of P\u00e9cs, Szigeti \u00fat 12, 7624 P\u00e9cs, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e9ter","family":"Hegyi","sequence":"additional","affiliation":[{"name":"Institute for Translational Medicine, Medical School, University of P\u00e9cs, Szigeti \u00fat 12, 7624 P\u00e9cs, Hungary"},{"name":"First Department of Medicine, University of Szeged, Kor\u00e1nyi Fasor 8-10, 6720 Szeged, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"T\u00f3th","sequence":"additional","affiliation":[{"name":"Department of Pharmacognosy, University of Szeged, E\u00f6tv\u00f6s u. 6, 6720 Szeged, Hungary"},{"name":"Interdisciplinary Centre of Natural Products, University of Szeged, Dugonics t\u00e9r 13, 6720 Szeged, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4088-3333","authenticated-orcid":false,"given":"Dezs\u0151","family":"Csupor","sequence":"additional","affiliation":[{"name":"Institute for Translational Medicine, Medical School, University of P\u00e9cs, Szigeti \u00fat 12, 7624 P\u00e9cs, Hungary"},{"name":"Department of Pharmacognosy, University of Szeged, E\u00f6tv\u00f6s u. 6, 6720 Szeged, Hungary"},{"name":"Interdisciplinary Centre of Natural Products, University of Szeged, Dugonics t\u00e9r 13, 6720 Szeged, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4914-9872","authenticated-orcid":false,"given":"Bal\u00e1zs","family":"N\u00e9meth","sequence":"additional","affiliation":[{"name":"Department of Public Health Medicine, Medical School, University of P\u00e9cs, Szigeti \u00fat 12, 7624 P\u00e9cs, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0746-8920","authenticated-orcid":false,"given":"Anita","family":"Luk\u00e1cs","sequence":"additional","affiliation":[{"name":"Department of Public Health, Faculty of Medicine, University of Szeged, D\u00f3m t\u00e9r 10, 6720 Szeged, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5915-0383","authenticated-orcid":false,"given":"L\u00e1szl\u00f3 M\u00e1rk","family":"Czumbel","sequence":"additional","affiliation":[{"name":"Department of Oral Biology, Faculty of Dentistry, Semmelweis University, Nagyv\u00e1rad t\u00e9r 4, 1089 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Be\u00e1ta","family":"Ker\u00e9mi","sequence":"additional","affiliation":[{"name":"Department of Oral Biology, Faculty of Dentistry, Semmelweis University, Nagyv\u00e1rad t\u00e9r 4, 1089 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Istv\u00e1n","family":"Kiss","sequence":"additional","affiliation":[{"name":"Department of Public Health Medicine, Medical School, University of P\u00e9cs, Szigeti \u00fat 12, 7624 P\u00e9cs, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4949-9431","authenticated-orcid":false,"given":"Andrea","family":"Szab\u00f3","sequence":"additional","affiliation":[{"name":"Department of Public Health, Faculty of Medicine, University of Szeged, D\u00f3m t\u00e9r 10, 6720 Szeged, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5506-8198","authenticated-orcid":false,"given":"G\u00e1bor","family":"Varga","sequence":"additional","affiliation":[{"name":"Department of Oral Biology, Faculty of Dentistry, Semmelweis University, Nagyv\u00e1rad t\u00e9r 4, 1089 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0256-2608","authenticated-orcid":false,"given":"G\u00e1bor","family":"Gerber","sequence":"additional","affiliation":[{"name":"Department of Anatomy, Histology and Embryology, Faculty of Medicine, Semmelweis University, T\u0171zolt\u00f3 u. 58, 1094 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9330-9119","authenticated-orcid":false,"given":"Zolt\u00e1n","family":"Gy\u00f6ngyi","sequence":"additional","affiliation":[{"name":"Department of Public Health Medicine, Medical School, University of P\u00e9cs, Szigeti \u00fat 12, 7624 P\u00e9cs, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,3,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","unstructured":"American Cancer Society (2022). Breast Cancer Facts & Figures 2022\u20132024, American Cancer Society, Inc.. Available online: https:\/\/www.cancer.org\/research\/cancer-facts-statistics\/breast-cancer-facts-figures.html."},{"key":"ref_3","unstructured":"Cancer Research UK (2024, February 07). Breast Cancer (C50), Average Number of New Cases per Year and Age-Specific Incidence Rates per 100,000 Females, UK, 2016\u20132018. Available online: https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/breast-cancer\/incidence-invasive#heading-One."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1007\/s11307-022-01795-1","article-title":"Recent Trends in Diagnostic Biomarkers of Tumor Microenvironment","volume":"25","author":"Siminzar","year":"2023","journal-title":"Mol. Imaging Biol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e012312","DOI":"10.1136\/bmjgh-2023-012312","article-title":"Secular trends in premature and early menopause in low-income and middle-income countries","volume":"8","author":"Leone","year":"2023","journal-title":"BMJ Glob. Health"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.1038\/s41467-023-39613-z","article-title":"Molecular profiling of aromatase inhibitor sensitive and resistant ER+ HER2-postmenopausal breast cancers","volume":"14","author":"Schuster","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/lipd.12011","article-title":"Differential Effects of Estrogen and Progestin on Apolipoprotein B100 and B48 Kinetics in Postmenopausal Women","volume":"53","author":"Diffenderfer","year":"2018","journal-title":"Lipids"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/978-3-319-70178-3_12","article-title":"Role of Estrogens in the Regulation of Liver Lipid Metabolism","volume":"1043","author":"Palmisano","year":"2017","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12944-024-02002-6","article-title":"Lipid changes during endocrine therapy in early-stage breast cancer patients: A real-world study","volume":"23","author":"Li","year":"2024","journal-title":"Lipids Health Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"101667","DOI":"10.1016\/j.beem.2022.101667","article-title":"Effects of endocrine disorders on lipids and lipoproteins","volume":"37","author":"Newman","year":"2023","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1161\/ATVBAHA.118.310792","article-title":"Estrogen Inhibits LDL (Low-Density Lipoprotein) Transcytosis by Human Coronary Artery Endothelial Cells via GPER (G-Protein-Coupled Estrogen Receptor) and SR-BI (Scavenger Receptor Class B Type 1)","volume":"38","author":"Ghaffari","year":"2018","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"895916","DOI":"10.3389\/fcvm.2022.895916","article-title":"Estrogen Mediates an Atherosclerotic-Protective Action via Estrogen Receptor Alpha\/SREBP-1 Signaling","volume":"9","author":"Xie","year":"2022","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"850815","DOI":"10.3389\/fphar.2022.850815","article-title":"The Effects of Menopause Hormone Therapy on Lipid Profile in Postmenopausal Women: A Systematic Review and Meta-Analysis","volume":"13","author":"Nie","year":"2022","journal-title":"Front. Pharmacol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Iorga, A., Cunningham, C.M., Moazeni, S., Ruffenach, G., Umar, S., and Eghbali, M. (2017). The protective role of estrogen and estrogen receptors in cardiovascular disease and the controversial use of estrogen therapy. Biol. Sex Differ., 8.","DOI":"10.1186\/s13293-017-0152-8"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.tem.2018.06.001","article-title":"Extragonadal effects of follicle-stimulating hormone on osteoporosis and cardiovascular disease in women during menopausal transition","volume":"29","author":"Zhu","year":"2018","journal-title":"Trends. Endocrinol. Metab."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1093\/aje\/kwp043","article-title":"Lipid changes during the menopause transition in relation to age and weight: The Study of Women\u2019s Health Across the Nation","volume":"169","author":"Derby","year":"2009","journal-title":"Am. J. Epidemiol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1097\/gme.0b013e3181dbdc30","article-title":"Serum lipid profile changes during the menopausal transition in Chinese women: A community-based cohort study","volume":"17","author":"Zhou","year":"2010","journal-title":"Menopause"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1093\/oxfordjournals.aje.a116686","article-title":"Perimenopausal increase in serum cholesterol: A 10-year longitudinal study","volume":"137","author":"Korevaar","year":"1993","journal-title":"Am. J. Epidemiol."},{"key":"ref_19","first-page":"168","article-title":"Association of comorbidities with breast cancer: An observational study","volume":"19","author":"Sharma","year":"2015","journal-title":"Trop. J. Med. Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"R64","DOI":"10.1186\/bcr2901","article-title":"Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: A retrospective cohort study","volume":"13","author":"Patnaik","year":"2011","journal-title":"Breast Cancer Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"596","DOI":"10.2174\/092986713804999303","article-title":"Treatment of estrogen receptor-positive breast cancer","volume":"20","author":"Lumachi","year":"2013","journal-title":"Curr. Med. Chem."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1093\/jnci\/djr242","article-title":"Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: A systematic review and meta-analysis","volume":"103","author":"Amir","year":"2011","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Boszkiewicz, K., Piwowar, A., and Petryszyn, P. (2022). Aromatase Inhibitors and Risk of Metabolic and Cardiovascular Adverse Effects in Breast Cancer Patients\u2014A Systematic Review and Meta-Analysis. J. Clin. Med., 11.","DOI":"10.3390\/jcm11113133"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.3390\/curroncol30020142","article-title":"Risk of Cardiovascular Events and Lipid Profile Change in Patients with Breast Cancer Taking Aromatase Inhibitor: A Systematic Review and Meta-Analysis","volume":"30","author":"Yoo","year":"2023","journal-title":"Curr. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G., and PRISMA Group (2009). Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med., 6.","DOI":"10.1371\/journal.pmed.1000097"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: Checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann. Intern. Med."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Higgins, J.P.T., Thomas, J., Chandler, J., Cumpston, M., Li, T., Page, M.J., and Welch, V.A. (2019). Cochrane Handbook for Systematic Reviews of Interventions, John Wiley & Sons. [2nd ed.].","DOI":"10.1002\/9781119536604"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/001316446002000104","article-title":"A coefficient of agreement for nominal scales","volume":"20","author":"Cohen","year":"1960","journal-title":"Educ. Psychol. Meas."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.cct.2015.09.002","article-title":"Meta-analysis in clinical trials revisited","volume":"45 Pt A","author":"DerSimonian","year":"2015","journal-title":"Contemp. Clin. Trials."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"5126","DOI":"10.1200\/JCO.2005.07.097","article-title":"Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer","volume":"23","author":"Geisler","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/sj.bjc.6603258","article-title":"Exemestane after tamoxifen as adjuvant hormonal therapy in postmenopausal women with breast cancer: Effects on body composition and lipids","volume":"95","author":"Francini","year":"2006","journal-title":"Br. J. Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.ejim.2007.05.016","article-title":"The effects on lipid serum levels of a 2-year adjuvant treatment with exemestane after tamoxifen in postmenopausal women with early breast cancer","volume":"19","author":"Montagnani","year":"2008","journal-title":"Eur. J. Intern. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/annonc\/mdn545","article-title":"Lipid changes in breast cancer patients on exemestane treatment: Final results of the TEAM Greek substudy","volume":"20","author":"Markopoulos","year":"2009","journal-title":"Ann. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"R35","DOI":"10.1186\/bcr2320","article-title":"Extended adjuvant hormonal therapy with exemestane has no detrimental effect on the lipid profile of postmenopausal breast cancer patients: Final results of the ATENA lipid substudy","volume":"11","author":"Markopoulos","year":"2009","journal-title":"Breast Cancer Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1080\/02841860510007585","article-title":"Effect of anastrozole and tamoxifen on lipid metabolism in Japanese postmenopausal women with early breast cancer","volume":"44","author":"Sawada","year":"2005","journal-title":"Acta Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1634\/theoncologist.2009-0222","article-title":"Effect of letrozole on plasma lipids, triglycerides, and estradiol in postmenopausal women with metastatic breast cancer","volume":"15","author":"Zidan","year":"2010","journal-title":"Oncologist"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s10549-011-1608-x","article-title":"Effects of toremifene and anastrozole on serum lipids and bone metabolism in postmenopausal females with estrogen receptor-positive breast cancer: The results of a 2-year multicenter open randomized study","volume":"128","author":"Anan","year":"2011","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1177\/0091270011424153","article-title":"Comparison of changes in the lipid profile of postmenopausal women with early stage breast cancer treated with exemestane or letrozole","volume":"52","author":"Bell","year":"2012","journal-title":"J. Clin. Pharmacol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s10549-013-2573-3","article-title":"A randomized, double-blind, controlled study of exemestane versus anastrozole for the first-line treatment of postmenopausal Japanese women with hormone-receptor-positive advanced breast cancer","volume":"139","author":"Iwata","year":"2013","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1158\/1078-0432.CCR-15-1213","article-title":"Association of Variants in Candidate Genes with Lipid Profiles in Women with Early Breast Cancer on Adjuvant Aromatase Inhibitor Therapy","volume":"22","author":"Blackford","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1158\/1940-6207.CAPR-15-0322","article-title":"Double-Blind, Randomized Trial of Alternative Letrozole Dosing Regimens in Postmenopausal Women with Increased Breast Cancer Risk","volume":"9","author":"Pruthi","year":"2016","journal-title":"Cancer Prev. Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1158\/1940-6207.CAPR-15-0269","article-title":"Exemestane Use in Postmenopausal Women at High Risk for Invasive Breast Cancer: Evaluating Biomarkers of Efficacy and Safety","volume":"9","author":"Venzon","year":"2016","journal-title":"Cancer Prev. Res."},{"key":"ref_43","first-page":"142","article-title":"Effects of tamoxifen or letrozole on lipid profile, vitamin D and estradiol serum levels in obese postmenopausal woman with breast cancer","volume":"9","author":"Sahib","year":"2017","journal-title":"Int. J. Pharm. Sci."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/cpdd.420","article-title":"Comparison of changes in the lipid profiles of Eastern Chinese postmenopausal women with early-stage breast cancer treated with different aromatase inhibitors: A retrospective study","volume":"7","author":"Tian","year":"2018","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1016\/j.jacc.2018.11.002","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_46","first-page":"2620","article-title":"Advances in aromatase inhibition: Clinical efficacy and tolerability in the treatment of breast cancer","volume":"7","author":"Buzdar","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"111680","DOI":"10.1016\/j.exger.2021.111680","article-title":"The effect of tamoxifen on the lipid profile in women: A systematic review and meta-analysis of randomized controlled trials","volume":"159","author":"Alomar","year":"2022","journal-title":"Exp. Gerontol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/01.gme.0000218683.97338.ea","article-title":"Postmenopausal status and early menopause as independent risk factors for cardiovascular disease: A meta-analysis","volume":"13","author":"Atsma","year":"2006","journal-title":"Menopause"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"445","DOI":"10.3109\/13697137.2011.562994","article-title":"Impact of surgical menopause on lipid and bone metabolism","volume":"14","author":"Yoshida","year":"2011","journal-title":"Climacteric"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"v8","DOI":"10.1093\/annonc\/mdv298","article-title":"Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Senkus","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1007\/s40265-017-0767-4","article-title":"The Effects of Tamoxifen on Plasma Lipoprotein(a) Concentrations: Systematic Review and Meta-Analysis","volume":"77","author":"Sahebkar","year":"2017","journal-title":"Drugs"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/j.metabol.2006.03.005","article-title":"Effects of raloxifene on lipid and lipoprotein levels in postmenopausal osteoporotic women with and without hypertriglyceridemia","volume":"55","author":"Dayspring","year":"2006","journal-title":"Metabolism"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa062462","article-title":"Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women","volume":"355","author":"Mosca","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.4161\/cbt.8.15.8959","article-title":"Fulvestrant treatment is associated with cholesterol plasma level reduction in hormone-receptor-positive metastatic breast cancer patients","volume":"8","author":"Camerini","year":"2009","journal-title":"Cancer Biol. Ther."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ejogrb.2024.01.021","article-title":"The effect of exemestane administration on the lipid profile in women: Meta-analysis of randomised controlled trials","volume":"295","author":"Yang","year":"2024","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"478","DOI":"10.6004\/jadpro.2023.14.6.2","article-title":"Precautions for patients taking tamoxifen or aromatase inhibitors","volume":"14","author":"Heery","year":"2023","journal-title":"J. Adv. Pract. Oncol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/6\/1818\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:17:25Z","timestamp":1760105845000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/6\/1818"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,21]]},"references-count":56,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["jcm13061818"],"URL":"https:\/\/doi.org\/10.3390\/jcm13061818","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,21]]}}}